▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

David Phillips

10qdetective

David J. Phillips, a contributing editor to Fool.com, is a former equity analyst. He holds an MBA from Boston College.

Recent Articles by David Phillips

Mar 27, 2014 by David Phillips

Can AbbVie's Legacy Products Deliver Further Growth?

AbbVie is spending more than 16% of annual sales to develop new drugs that will lesson the drug maker's dependence on the rheumatoid arthritis drug Humira. Fortunately, the Chicago-based drug manufacturer has a stable of off-patent, legacy drugs that contribute sizable sales to this R&D effort.

Mar 8, 2014 by David Phillips

AbbVie's Humira Still a Growth Engine

A published survey of rheumatologists suggests that growth in key European markets for AbbVie’s (NYSE: ABBV) flagship drug Humira could stall as biosimilar options become more prevalent. Absent longer-term safety data on these follow-on drugs, Humira should continue to shine.

Mar 3, 2014 by David Phillips

Pfizer Stubs Toe Without Celebrex

Pfizer (NYSE: PFE) remains committed to maintaining a leadership position in global pain-treatment markets, despite the upcoming loss of market exclusivity for Celebrex. Foolish investors should remain wary of management promises.

Feb 25, 2014 by David Phillips

Zogenix Stockholders Facing World of Pain?

The share price of Zogenix has soared more than 260% during the past year, driven by investor optimism for new opioid painkiller Zyhydro ER. Will the drug be a commercial success?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services